Webinar replay

Setting a Strategy for Partnering Success

Ipsen is a mid-size pharma company that punches well above its weight. Fresh off its acquisition of Albireo and with more deals on the horizon for 2023, Ipsen is preparing for another successful year of biopharma partnering – but what is their strategy, how do they make the deals happen, and what are the tools they use to get it done? 

Philippe Lopes-Fernandes, Executive Vice President and Chief Business Officer of Ipsen, joins Inova CEO Gilles Toulemonde to explore how he structured his partnering team, where their therapeutic focus lies, how innovative biotechs and academic labs can get on the Ipsen radar, and how to make the most out your presence at partnering meetings. 

  • Ipsen’s dealmaking strategy and the advantages of partnering with a mid-sized firm 
  • Tactics and best practices to ensure successful engagement with pharma partners 
  • How digital tools like Inova support partnering excellence from sourcing to execution and reputation  
Watch this replay to get expert insights from our panelists:
philippe-lopes-fernandes-ipsen
Philippe Lopes-Fernandes
Executive Vice President and CBO
Ipsen
gilles-toulemonde-square
Gilles Toulemonde
CEO
Inova

Please complete the form below

All fields marked with a * are required.
By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.

Resources you may be interested in

samson-ZGjbiukp_-A-unsplash

Biopharma Dealmaking in 2023. Perspective and Projections

Watch webinar replay
partnering2030

Partnering 2030: The Biotech Perspective

Get the report
5-Keys-to-Optimizing-hero-1

5 Keys to Optimizing Biopharma Business Development

Download whitepaper

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.